Comparing Contrave to a GLP-1 like Wegovy or Saxenda? Absolutely — here’s a clear side-by-side comparison of Contrave vs. GLP-1 drugs like Wegovy (semaglutide) and Saxenda (liraglutide) to help you understand how they differ: ⚖️ Contrave vs. GLP-1s (Wegovy & Saxenda) Feature Contrave Wegovy (Semaglutide) Saxenda (Liraglutide) Drug Class Bupropion (antidepressant) + Naltrexone (opioid blocker) […]
Author Archives: admin
Bupropion/naltrexone, sold under the brand name Contrave, is a prescription weight loss medication approved for adults who are overweight or obese. It’s not a GLP-1 drug (like Wegovy or Saxenda) — instead, it works on the brain to help reduce appetite and control cravings. ⚙️ What Is Contrave? Medication Contrave (bupropion + naltrexone) Drug Class […]
Liraglutide (Saxenda) is generally well-tolerated, but like all medications, it can cause side effects — some common and mild, others rare and potentially serious. ✅ Common Side Effects These are usually mild to moderate, especially when starting the medication or increasing the dose: Side Effect Details Nausea Most common; occurs in up to 40% of […]
Liraglutide (brand name: Saxenda) is a prescription weight loss medication that belongs to a class of drugs called GLP-1 receptor agonists (glucagon-like peptide-1). It was one of the first medications in this class approved for chronic weight management, and it is also used under a different name (Victoza) for type 2 diabetes. 🔍 Quick Overview […]
Weight loss drugs have become significantly more effective in recent years — far beyond what was available even a decade ago. Here’s a breakdown of how effective they are, based on clinical trial data from the most commonly studied medications: 🔥 Average Weight Loss from Popular Drugs Medication Average Weight Loss Timeframe Notes Semaglutide (Wegovy) […]
Great question! The safety of new weight loss drugs depends on several factors, including the specific medication, your health status, and how it’s used. Here’s a quick overview: ✔️ What We Know About Safety of New Weight Loss Drugs ⚠️ What You Should Keep in Mind Bottom line: New weight loss drugs have shown promising […]
Orforglipron (LY3502970) is an investigational oral GLP-1 receptor agonist developed by Eli Lilly, currently undergoing clinical trials for the treatment of type 2 diabetes and obesity. While it offers the convenience of a daily pill, it’s important to be aware of potential side effects. ⚠️ Common Side Effects The most frequently reported side effects of […]
Orforglipron is an investigational oral medication developed by Eli Lilly, designed to treat type 2 diabetes and support weight loss in individuals with obesity or overweight. It is a small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist, differing from traditional peptide-based GLP-1 drugs like semaglutide and tirzepatide. Unlike these injectables, orforglipron is taken once daily in pill […]
Side Effects of CagriSema (Cagrilintide + Semaglutide) CagriSema is an experimental combination therapy developed by Novo Nordisk, combining cagrilintide (an amylin analog) and semaglutide (a GLP-1 receptor agonist). While it has demonstrated significant weight loss benefits in clinical trials, it is important to be aware of potential side effects. Common Side Effects: Less Common Side […]
Here’s an illustrative chart showing average weight-loss outcomes across different therapies—including CagriSema versus semaglutide (Wegovy) and tirzepatide. It highlights CagriSema’s impressive performance in clinical settings. What Is CagriSema? CagriSema is an experimental combination therapy being developed by Novo Nordisk that merges two distinct hormone analogs into a single once-weekly injection: This fixed-dose combination, administered subcutaneously […]